31 March 2022 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in Realtime iCMR cardiac ablation products, is pleased to announce it has entered into a Development Agreement with Mammendorfer Institut für Physik und Medizin GmbH (MIPM), a leading developer and manufacturer of MRI-compatible medical devices, including an MRI-compatible external cardioverter defibrillator. MIPM is headquartered in Mammendorf, Germany. Performing cardiac ablation of complex arrythmia, such as VT, requires an external cardioverter defibrillator. MIPM has developed such a system.  Imricor’s Vice President of Marketing and Business Development, Nick Twohy, said: “We are thrilled to be aligned with a world leader in providing MRI-compatible devices. MIPM’s defibrillator and technology are critical to the success of performing complex iCMR ablations.” Under the terms of the agreement, Imricor and MIPM will collaborate on product development and clinical trials, including Imricor’s upcoming trial for expanded indications to VT ablation procedures in the iCMR. Andreas Klement, Vice President, MIPM, stated, “MIPM is very happy about the cooperation with Imricor and expects a long-term and fruitful cooperation in this innovative field of electrophysiological examinations and ablation procedures in the MR-Environment.”

11 February 2022 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in realtime iCMR cardiac ablation products, today announced the scheduled retirement of its Chief Financial Officer, Ms Lori Milbrandt, and the appointment of Mr Jonathon Gut as the incoming Chief Financial Officer.

4 January 2022 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in realtime iCMR cardiac ablation products, is pleased to announce that the Henry Dunant Hospital Centre in Athens, Greece (https://www.dunant.gr/en/) is the latest institution to adopt Imricor’s iCMR ablation solutions.

28 December 2021 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in realtime iCMR cardiac ablation products, is pleased to announce that the German Heart Centre Berlin (https://www.dhzb.de/en/), and the Charité Medical University, Virchow-Klinikum Campus (Charité) (https://www.charite.de/en/), both in Berlin, Germany, are the latest two institutions to adopt Imricor’s iCMR ablation solutions.

13 October 2021 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in iCMR-guided cardiac ablation products, is pleased to announce that the Semmelweis University Heart and Vascular Centre in Budapest Hungary, has signed a purchase agreement with Imricor, making it the eleventh site to establish an iCMR lab to perform ablations with Imricor’s products.

30 August 2021 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce it has entered into a Sales Distribution Agreement with NordicNeuroLab AS, a leading maker of MRI compatible in-room monitors, headquartered in Norway.

lobal leader in MRI-guided cardiac ablation products, has achieved an important milestone in its geographic expansion plans with the Company’s Advantage-MR EP Recorder/Stimulator system receiving Australian TGA approval.

2 April 2021 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce it has entered into a Distribution Agreement with Australian-owned medical distribution company Regional Health Care Group Pty Ltd (RGCH), based in Sydney.

8 March 2021 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce the Helios Leipzig Heart Centre in Germany has commenced procedures.

24 February 2021 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce the Maastricht University Medical Centre+ (MUMC+) in the Netherlands has commenced procedures since the extended lockdowns across Europe precluded elective surgeries. The team at MUMC+ successfully performed two atrial flutter ablations yesterday.